⚕ GalenOps field
←

714-1068

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
714 (USA) · Dr. Clarke
consented 2013-08-08

AEs
6
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-09-20 (study day 44.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-09-20 (study day 44.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-09-20 (study day 44.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-09-20 (study day 44.0); relationship: PROBABLE

moderate assessed

Moderate SKIN IRRITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-12 (study day 5.0); relationship: PROBABLE

moderate assessed

Moderate SKIN IRRITATION — outcome: RECOVERED/RESOLVED; onset 2013-08-12 (study day 5.0); relationship: PROBABLE

Data queries

No data queries.